1. Home
  2. CLLS vs BYND Comparison

CLLS vs BYND Comparison

Compare CLLS & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • BYND
  • Stock Information
  • Founded
  • CLLS 1999
  • BYND 2009
  • Country
  • CLLS France
  • BYND United States
  • Employees
  • CLLS N/A
  • BYND 754
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • BYND Packaged Foods
  • Sector
  • CLLS Health Care
  • BYND Consumer Staples
  • Exchange
  • CLLS Nasdaq
  • BYND Nasdaq
  • Market Cap
  • CLLS 299.0M
  • BYND 183.2M
  • IPO Year
  • CLLS 2007
  • BYND 2019
  • Fundamental
  • Price
  • CLLS $2.85
  • BYND $2.45
  • Analyst Decision
  • CLLS Buy
  • BYND Sell
  • Analyst Count
  • CLLS 1
  • BYND 4
  • Target Price
  • CLLS $4.00
  • BYND $3.67
  • AVG Volume (30 Days)
  • CLLS 199.3K
  • BYND 2.2M
  • Earning Date
  • CLLS 08-04-2025
  • BYND 08-06-2025
  • Dividend Yield
  • CLLS N/A
  • BYND N/A
  • EPS Growth
  • CLLS N/A
  • BYND N/A
  • EPS
  • CLLS N/A
  • BYND N/A
  • Revenue
  • CLLS $63,438,000.00
  • BYND $301,353,000.00
  • Revenue This Year
  • CLLS N/A
  • BYND N/A
  • Revenue Next Year
  • CLLS $4.90
  • BYND $3.36
  • P/E Ratio
  • CLLS N/A
  • BYND N/A
  • Revenue Growth
  • CLLS 223.09
  • BYND N/A
  • 52 Week Low
  • CLLS $1.10
  • BYND $2.23
  • 52 Week High
  • CLLS $3.24
  • BYND $7.60
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 59.27
  • BYND 33.05
  • Support Level
  • CLLS $2.71
  • BYND $2.35
  • Resistance Level
  • CLLS $3.08
  • BYND $2.89
  • Average True Range (ATR)
  • CLLS 0.20
  • BYND 0.13
  • MACD
  • CLLS -0.03
  • BYND -0.04
  • Stochastic Oscillator
  • CLLS 61.67
  • BYND 13.16

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: